The phase III MYSTIC trial assessed the first-line efficacy of the anti-PD-L1 agent durvalumab – given alone or alongside the CTLA-4 blocker tremelimumab – versus platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer. The combination previously failed to show a significant progression-free or overall survival benefit, but additional analyses of the trial are ongoing.
Results
One analysis, focusing on patients with high tumor mutational burden was presented at the World Conference on Lung Cancer 2019. The investigators found that patients harboring STK11 and KEAP1 mutations had a poor prognosis, while those with ARID1A mutations had improved overall survival when treated with durvalumab plus tremelimumab.